Abstract:

BACKGROUND: Studies have shown that rifampicin or isoniazid covered with biodegradable sustained release materials can be used to prepare pulmonary targeting microspheres with less than 50 μm sustained-release degradation, which are mainly used for lung targeted therapy via the intravenous injection.
OBJECTIVE: To develop long-term slow-release two-component drug artificial bone and to select the optimal preparation process of drug release as well as to observe the characteristics of in vitro releases.
METHODS: Orthogonal design was adopted to optimize the preparation technology using the emulsion-solvent evaporation method of preparation technology. We prepared rifampicin poly(lactic-co-glycolic acid) copolymer microspheres and isoniazid poly(lactic-co-glycolic acid) copolymer microspheres. Biological binder was used to process these two kinds of microspheres into long-term slow-release two-component drug artificial bone.
RESULTS AND CONCLUSION: According to the process optimization, two kinds of poly(lactic-co-glycolic acid) copolymer microspheres carrying 26% rifampicin or 28% isoniazid were prepared successfully, which were used to prepare artificial bone at a quality of 50%. The drug concentrations were kept at 0.02 and 0.03 mg/L after 90 days of in vitro release. These findings indicate that this kind of artificial bone is expected to provide a new and effective treatment for bone tuberculosis.